Cytokinetics (CYTK) EBIAT (2016 - 2025)
Cytokinetics (CYTK) has disclosed EBIAT for 16 consecutive years, with -$345.4 million as the latest value for Q4 2025.
- Quarterly EBIAT changed N/A to -$345.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$947.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$785.0 million for FY2025, 33.15% down from the prior year.
- EBIAT for Q4 2025 was -$345.4 million at Cytokinetics, down from -$306.2 million in the prior quarter.
- The five-year high for EBIAT was -$19.8 million in Q2 2022, with the low at -$345.4 million in Q4 2025.
- Average EBIAT over 5 years is -$132.5 million, with a median of -$134.4 million recorded in 2025.
- The sharpest move saw EBIAT plummeted 2296.41% in 2021, then soared 67.8% in 2022.
- Over 5 years, EBIAT stood at -$30.6 million in 2021, then tumbled by 349.39% to -$137.4 million in 2022, then increased by 0.35% to -$136.9 million in 2023, then decreased by 17.28% to -$160.5 million in 2024, then plummeted by 115.17% to -$345.4 million in 2025.
- According to Business Quant data, EBIAT over the past three periods came in at -$345.4 million, -$306.2 million, and -$134.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.